Atlas Trials

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

Clinical trial NCT05303532 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT05303532
Sponsor
AstraZeneca
Status
ENROLLING_BY_INVITATION
Phase
Phase 3
Study type
INTERVENTIONAL
Cancer
Start date
2022-04-19
Primary completion
2026-12-31
Enrollment
214

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.